Defining Juvenile Idiopathic Arthritis Remission and Optimum Time for Disease-Modifying Anti-Rheumatic Drug Withdrawal: Why We Need a Consensus

Author： Broughton Thomas

Publisher： Adis International

ISSN： 1174-5878

Source： Pediatric Drugs, Vol.14, Iss.1, 2012-02, pp. : 7-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis

By Fleischmann Roy

Expert Opinion on Drug Safety, Vol. 2, Iss. 4, 2003-07 ,pp. : 347-365

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine

By Umićević Mirkov Maša Coenen Marieke JH

Pharmacogenomics, Vol. 14, Iss. 4, 2013-03 ,pp. : 425-444

Future Medicine

Access to resources Recommend Favorite

Clinically Important Drug Interactions with Disease-Modifying Antirheumatic Drugs

By Haagsma C.J.

Drugs & Aging, Vol. 13, Iss. 4, 1998-10 ,pp. : 281-289

Adis International

Access to resources Recommend Favorite

Safety and Efficacy of Disease-Modifying Anti-Rheumatic Agents: Focus on the Benefits and Risks of Etanercept

By Fleischmann R.

Drug Safety, Vol. 25, Iss. 3, 2002-01 ,pp. : 173-197

Adis International

Access to resources Recommend Favorite

Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

By Nurmohamed Michael T. Dijkmans Ben A.C.

Drugs, Vol. 65, Iss. 5, 2005-01 ,pp. : 661-694

Adis International

Access to resources Recommend Favorite